HZNP NEWS! 12.02 Horizon Pharma Inc (HZNP)

New Post Public Reply Private Reply Replies (0) Message Board

Apr 13, 2014 at 6:53 PM

Horizon Pharma Inc (HZNP) 12.02 $HZNP

Recent Acquisitions, Trial Opinions, Upcoming Earnings, Inducement Grants, and Clinical Trial Results - Analyst Notes on Actavis, The Medicines Company, Hospira, Horizon Pharma, and Galectin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), The Medicines Company (NASDAQ: MDCO), Hospira, Inc. (NYSE: HSP), Horizon Pharma, Inc. (NASDAQ: HZNP), and Galectin Therapeutics Inc. (NASDAQ: GALT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Horizon Pharma announces Notice of Allowance for US Patent Application for RAYOS for treating a broad range of diseases
M2 - Fri Apr 11, 4:56AM CDT
Specialist pharmaceutical company Horizon Pharma (NASDAQ:HZNP) revealed on Thursday the receipt of Notice of Allowance for US Patent Application 13/713,528 entitled "Delayed-Release Tablet with Defined Core Geometry" that covers its US approved product RAYOS.

Horizon Pharma (HZNP): An Off-the-Radar Potential Winner - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:33AM CDT
Horizon Pharma looks well positioned for a solid gain, but has been overlooked by investors lately. This Generic Drugs stock has actually seen estimates rise over the past month for the current fiscal year. This year’s expected earnings growth over the prior year is 147.1%, which should ultimately translate into price appreciation.

Horizon Pharma Announces the U.S. Patent and Trademark Office Issued an Additional Notice of Allowance With Claims Covering RAYOS(R) (Prednisone) Delayed-Release Tablets
Marketwire - Thu Apr 10, 6:30AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Skyepharma has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application 13/713,528 entitled "Delayed-Release Tablet with Defined Core Geometry" that covers the Company's U.S. approved product RAYOS(R).

Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 03, 12:47PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:

Technical Data on Top Gainers -- Research on JinkoSolar, Horizon Pharma, YY Inc., and Questcor Pharma
PR Newswire - Wed Apr 02, 8:59AM CDT
On Tuesday, April 01, 2014, the US markets saw a positive sentiment, with the NASDAQ Composite closing at 4,268.04, up 1.64%, the Dow Jones Industrial Average ending the session at 16,532.61, up 0.46% and the S&P 500 edging 0.70% higher to finish the trading session at 1,885.52. The session saw a positive impact from Consumer Discretionary, Information Technology and Industrials sectors along with a drag from Utilities, and Consumer Staples sectors. A number of stocks saw large movements, including JinkoSolar Holding Co. Ltd (NYSE: JKS), Horizon Pharma Inc. (NASDAQ: HZNP), YY Inc. (NASDAQ: YY) and Questcor Pharmaceuticals Inc. (NASDAQ: QCOR). Free technical research on JKS, HZNP, YY and QCOR can be downloaded upon signing up at:

Biotechs Giving Uncle Sam the Shaft
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 5:08PM CDT
As they say in real estate: location, location, location. Biotechs have been acquiring companies in large part for their address. Specifically, they're buying so they can move to places like Ireland, where taxes are substantially lower than in the...

Horizon Pharma grants inducement stock options to 26 new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Mar 28, 4:55AM CDT
Pharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Thursday that it has awarded inducement stock options to purchase an aggregate of 96,750 shares of its common stock to 26 new employees.

Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marketwire - Thu Mar 27, 9:20PM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that on March 27, 2014 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 96,750 shares of common stock to 26 new employees.

Can Horizon Pharma (HZNP) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 7:47AM CDT
Positive earnings estimate revisions suggest that analysts are becoming more optimistic on HZNP’s earnings for the coming quarter and year.

Acquisitions, Appointments, and New Product Developments - Analyst Notes on Boston Scientific, Horizon Pharma, Alkermes, Agilent, and BD
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Boston Scientific Corporation (NYSE: BSX), Horizon Pharma Inc. (NASDAQ: HZNP), Alkermes Plc (NASDAQ: ALKS), Agilent Technologies Inc. (NYSE: A), and Becton, Dickinson and Co. (NYSE: BDX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews

Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

Is A Short Squeeze Ahead for Horizon Pharma (HZNP)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 8:18AM CDT
Is A Short Squeeze Ahead for Horizon Pharma (HZNP)?

Horizon Pharma to Present at the 21st Annual Future Leaders in the Biotech Industry Conference
Marketwire - Tue Mar 25, 6:31AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, its chairman, president and chief executive officer, will present at the 21st Annual Future Leaders in the Biotech Industry Conference on Friday, March 28, 2014 at 3:30 p.m. Eastern Time in New York, NY. Mr. Walbert will provide an overview of Horizon and its corporate activities.

Roundtable Top Picks for the Week of Mar. 24th - Video Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 3:52PM CDT
Ideas for Auto Parts, Financials and Pharmaceuticals. Opportunities covered include Motorcar Parts of America, Inc. (MPAA), Financial Select Sector SPDR Fund (XLF) and Horizon Pharmaceutical (HZNP).

3 Stocks Rising on Unusual Volume
at The Street - Mon Mar 24, 7:50AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Horizon Pharma to Host Corporate Update Meeting on March 27, 2014
Marketwire - Mon Mar 24, 6:30AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) will host a Corporate Update Meeting on Thursday, March 27, 2014 at 7:30 a.m. Eastern Time in New York, NY.

When Avoiding U.S. Taxes Is a Smart Play
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Mar 23, 5:20PM CDT
One of the big winners in the pharmaceuticals space this week was Horizon Pharma , up 17% in a single day on news that it was moving to Ireland to avoid higher U.S. tax rates. The company accomplished the move by buying Ireland's own Vidara...

3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 22, 7:00AM CDT
Don't worry if you're already out of the hunt for the $1 billion that will be awarded to the person who picks every bracket correctly in the NCAA basketball playoffs. You still have a shot at making some money -- by investing in health care. This...

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Retirement Dreams Dashed: 61% Withdraw Early

By Olivia Taylor Updated Nov 14, 2026 Category News Views 342

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...